Peer-reviewed veterinary case report
Metronomic chemo does not improve survival for dogs with splenic
By Alexander, C K et al.·Published in The Journal of small animal practice·2019·New England Veterinary Oncology Group, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: The addition of metronomic chemotherapy does not improve outcome for canine splenic haemangiosarcoma.
- Species:
- dog
Plain-English summary
A group of dogs with splenic hemangiosarcoma (a type of cancer affecting the spleen) underwent surgery to remove the spleen, followed by chemotherapy. Some of these dogs received an additional treatment called metronomic chemotherapy, while others did not. The dogs that received only the standard chemotherapy had a median survival time of about 180 days, while those who received the extra treatment lived a bit longer, around 212 days. However, the study found that adding metronomic chemotherapy did not significantly improve the overall outcome for these dogs.
People also search for: dog splenic hemangiosarcoma treatment · dog cancer chemotherapy options · metronomic chemotherapy for dogs
Abstract
OBJECTIVES: To determine whether the addition of metronomic chemotherapy improved outcome for dogs with splenic haemangiosarcoma treated with splenectomy and adjuvant maximum tolerated dose chemotherapy. MATERIALS AND METHODS: Medical records were examined retrospectively for dogs with splenic haemangiosarcoma that had undergone splenectomy followed by anthracycline-based chemotherapy. Thirty-nine dogs underwent splenectomy followed by maximum tolerated dose chemotherapy with an anthracycline, cyclophosphamide, or both (Group 1). Twenty-two dogs underwent splenectomy followed by adjuvant maximum tolerated dose chemotherapy with an anthracycline, cyclophosphamide, or both, plus metronomic chemotherapy (Group 2). Dogs in both groups were further separated into those treated with either maximum tolerated dose anthracycline or maximum tolerated dose anthracycline and cyclophosphamide. RESULTS: Median progression-free survival was 165 days and median overall survival time was 180 days in Group 1. Median progression-free survival was 185 days and median overall survival time was 212 days in Group 2. In both groups, the overall survival was shorter in dogs that had received maximum tolerated dose cyclophosphamide. CLINICAL SIGNIFICANCE: The addition of metronomic to maximum tolerated dose chemotherapy protocols does not appear to improve outcome in dogs with splenic haemangiosarcoma treated with splenectomy and maximum tolerated dose chemotherapy.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/30209807/